Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

  • End date
    May 31, 2022
  • participants needed
  • sponsor
    M.D. Anderson Cancer Center
Updated on 7 May 2021
platelet count
cytotoxic drug
malignant glioma
brain tumor
anaplastic astrocytoma
recurrent malignant glioma
recurrent tumor
therapeutic conventional surgery
investigational agent


This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.



I. To determine the maximal tolerated dose (MTD) of allogeneic bone marrow-derived human mesenchymal stem cells (BM-hMSCs) loaded with the oncolytic adenovirus DNX-2401 (BM-hMSCs-DNX2401) administered by intra-arterial injection (i.e., transfemoral super-selective endovascular intracranial injection) in patients with recurrent glioblastoma (GBM), gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

II. To determine the local and systemic toxicity of allogeneic BM-hMSCs-DNX2401 administered by intra-arterial injection (i.e., transfemoral super-selective endovascular intracranial injection) in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

III. To determine at the molecular and cellular level the capacity of allogeneic BM-hMSCs-DNX2401 administered intra-arterially to home to and deliver DNX-2401 to recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma by analyzing post-treatment surgical brain tumor specimens for the expression and distribution of adenoviral proteins.


I. To assess shedding of adenovirus into the blood, sputum, and nasopharynx after intra-arterial administration of BM-hMSCs-DNX2401 in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

II. To assess the development of anti-adenovirus antibodies after intra-arterial administration of BM-hMSCs-DNX2401 in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

III. To evaluate immune-mediated cytokine responses after intra-arterial administration of BM-hMSCs-DNX2401 in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

IV. To assess anti-tumoral activity and to determine progression-free survival (PFS) and overall survival (OS) after intra-arterial administration of BM-hMSCs-DNX2401 in patients with recurrent GBM, gliosarcoma or wild-type IDH-1 anaplastic astrocytoma.

OUTLINE: This is a dose-escalation study.

PART I: Patients receive oncolytic adenovirus Ad5-DNX-2401 intra-arterially (IA) over 20-30 minutes on day 0.

PART II: Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes.

After completion of study treatment, patients in part I are followed up on days 1, 4, 7, and 14 of month 1, months 1.5, 3, and 4.5, every 2 months up to month 26, month 30, then every 6 months thereafter. Patients in part II will be followed up on the day after surgery, weeks 1, 2 and 4, months 2, 2.5, 4, 5.5 and 7, every 2 months until month 19, every 4 months until month 32, then every 6 months thereafter.

Condition Recurrent Malignant Glioma, Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma, Recurrent Gliosarcoma, IDH1 wt Allele
Treatment therapeutic conventional surgery, Oncolytic Adenovirus Ad5-DNX-2401
Clinical Study IdentifierNCT03896568
SponsorM.D. Anderson Cancer Center
Last Modified on7 May 2021


Yes No Not Sure

Inclusion Criteria

Subjects must be willing and able to provide informed consent, undergo and comply with all study assessments and adhere to the protocol schedule
Patients with recurrent malignant GBM or gliosarcoma will be eligible. Patients with recurrent anaplastic astrocytoma with wild-type IDH-1 gene will also be eligible if there is a significant enhancing mass on magnetic resonance imaging (MRI) because their prognosis/behavior is similar to GBM. A pathology report constitutes adequate documentation of histology for study inclusion. Subjects with an initial diagnosis of a lower grade glioma are eligible if a subsequent biopsy is determined to be GBM and there is a significant enhancing mass on MRI
Patients must show unequivocal evidence for tumor recurrence or progression by MRI scan after failing prior surgical resection, biopsy, chemotherapy or radiation. A baseline MRI must be performed within 24 days prior to registration. Biopsy is encouraged at the time of recurrence if it is unclear that there is recurrent tumor. However, biopsy is not required if the practicing physician thinks that there is adequate radiographic and clinical evidence for recurrence
Patients must be able to undergo endovascular treatment based on Doppler studies showing internal carotid artery (ICA) that is less than 50% occluded
For patients undergoing resection for biological endpoints, tumors must be surgically resectable at the time of baseline evaluation and craniotomy for tumor resection would be part of their standard medical care
Tumors must be > 1.0 cm in diameter with upper limit of 5 cm maximal diameter
Patients must have a Karnofsky performance score >= 70
Patients must have a life expectancy of at least 16 weeks
Absolute granulocyte count >= 1,500 prior to starting therapy
Platelet count of >= 75,000 prior to starting therapy
Serum glutamate pyruvate transaminase (SGPT) and serum glutamic oxaloacetic transaminase (SGOT) < 2 times institutional normal ranges prior to starting therapy
Bilirubin < 2 times institutional normal ranges prior to starting therapy
Creatinine < 2.0 times institutional normal prior to starting therapy
Prothrombin time (PT), partial thromboplastin time (PTT), and thrombin time within institutional normal limits after correction of nutritional deficiencies that may contribute to prolonged PT/PTT
Subjects who have received the following chemotherapies must have completed them within the following time periods prior to baseline/day 0 of hMSC-DNX2401 delivery with recovery from any drug-related toxic effects to grade 1, or less, severity: 4 weeks from cytotoxic agents (3 weeks from procarbazine or temozolomide, 2 weeks from vincristine), 6 weeks from nitrosoureas (lomustine [CCNU], carmustine [BCNU]), 4 weeks from any investigational agent, 1 week from non-cytotoxic agents
Patients must be 8 weeks from radiotherapy to minimize the potential for MRI changes related to radiation necrosis that might be misdiagnosed as progression of disease, or 4 weeks if a new lesion, relative to the pre-radiation MRI, develops that is outside the primary radiation field (beyond 80% isodose line). However, if a biopsy is undertaken prior to these times and this biopsy documents histological evidence for recurrent disease, then patients will be eligible regardless of the time after radiation
Patients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study
Women of childbearing potential must have a negative urine pregnancy test documented within 7 days prior to study initiation
Subjects and their partners must be willing to use effective birth control during the study and for up to 6 months following administration of hMSC-DNX2401. Birth control that is acceptable to use in this study
Using twice the normal protection of birth control (i.e., double-barrier) by using a condom AND spermicidal jelly or foam, or a diaphragm AND spermicidal jelly or foam. A spermicidal jelly or foam must be used in addition to a barrier method (e.g., condom or diaphragm)
Birth control pills ("The Pill")
Depot or injectable birth control
IUD (intrauterine device)
Birth control patch (e.g., Ortho Evra)
Surgical sterilization (i.e., tubal ligation or hysterectomy for women or vasectomy for men)

Exclusion Criteria

Histology other than astrocytoma grade IV (GBM or gliosarcoma), although astrocytoma grade III that is IDH-1 wild-type will be included
Tumor foci detected below the tentorium or beyond the cranial vault
Tumor within the posterior fossa
Tumor with leptomeningeal spread
Difficulty in obtaining vascular access for percutaneous procedure
Ipsilateral carotid stenosis (> 50%, by Doppler studies)
Thrombophilias or primary hematological diseases
Transfusions or medications (G-CSF) to treat pancytopenia or other hematological conditions < 28 days prior to baseline/day 0/hMSC-DNX2401 administration
Biologic/immunotherapy within 2 weeks of baseline
Clinical or laboratory evidence of inflammatory and/or autoimmune disorders
Any contraindication for undergoing MRI such as: individuals with pacemakers, epicardial pacer wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prosthesis, implants with potential magnetic properties, metallic bodies in the eyes, etc. In addition, subjects must present with tumor that is evaluable by MRI
Pregnant or nursing females
Evidence of active uncontrolled infection or unstable or severe intercurrent medical conditions. All subjects must be afebrile at baseline (i.e., < 38.0 degrees Celsius [C])
Any medical condition that precludes surgery or endovascular treatment
Alcoholism (dependency), alcohol or substance abuse within twelve (12) months prior to screening that has caused health consequences
Immunocompromised subjects or those with autoimmune conditions, active hepatitis (liver function tests > 2x normal) or human immunodeficiency virus (HIV) seropositivity
Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery. If the medication can be discontinued prior to DNX-2401 injection then the subject may be eligible following consultation with the study chair. Low weight heparin and Lovenox (enoxaparin) administered on a temporary limited basis for post procedure deep venous thrombosis (DVT) prophylaxis is permitted
History or current diagnosis of any medical or psychological condition that in the investigator's opinion, might interfere with the subject's ability to participate or inability to obtain informed consent because of psychiatric or complicating medical problems
Encephalitis, multiple sclerosis or other central nervous system (CNS) infection or primary CNS disease that would interfere with subject evaluation
Subjects with known Li-Fraumeni syndrome or with a known germ line deficit in the retinoblastoma gene or its related pathways
Subjects with significant systemic or major illnesses including but not limited to: congestive heart failure, ischemic heart disease, cerebrovascular disease (history of strokes or transient ischemic attacks [TIAs] in large vessel or small vessel distribution), kidney disease or renal failure, active liver disease, organ transplantation, or significant psychiatric disorder
Enrollment in a concomitant therapeutic clinical study
Any condition that prevents compliance with the protocol or adherence to therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note